Cell子刊：中山大学邓艳红/张剑威团队揭示结直肠癌免疫治疗新靶点——CTSD

Core Viewpoint - The study highlights the role of Cathepsin-D (CTSD) in immune evasion in microsatellite stable colorectal cancer (MSS CRC), suggesting that targeting CTSD can enhance the efficacy of anti-PD-1 therapies [2][3][5]. Group 1: Research Findings - CTSD is overexpressed in colorectal cancer, leading to immune evasion and treatment resistance [7]. - CTSD promotes the degradation of MHC-I through the lysosomal pathway, which hinders its recycling to the cell surface [5][7]. - Gene knockout or pharmacological inhibition of CTSD can block immune evasion and enhance the efficacy of anti-PD-1 therapy [6][9]. Group 2: Implications for Treatment - Targeting CTSD in conjunction with anti-PD-1 immunotherapy could potentially improve treatment outcomes for patients with MSS CRC [8][9].